Foghorn Therapeutics Executive Compensation (FY25)
FHTX · Executive and director compensation, fiscal 2024 to 2025
The Foghorn Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 24, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
116 figures on this page: 115 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Adrian Gottschalk: $1,559,562 → $2,361,027 (51.4% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Foghorn Therapeutics' chief executive and what were they paid?
Total compensation for Adrian Gottschalk, President and Chief Executive Officer, came to $2,361,027 in fiscal 2025. Gottschalk's total was 51.4% higher than the $1,559,562 reported for fiscal 2024.
What was Foghorn Therapeutics' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 99.0% support at the meeting held June 24, 2026.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Adrian Gottschalk President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Steven Bellon Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Alfonso Quintas-Cardama Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Adrian Gottschalk President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Steven Bellon Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Alfonso Quintas-Cardama Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Adrian Gottschalk | Option | — | — | — | — | — | — | ◇ |
| Alfonso Quintas-Cardama | Option | — | — | — | — | — | — | ◇ |
| Steven Bellon | Option | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Steven Bellon | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Adrian Gottschalk | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Alfonso Quintas-Cardama | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Adrian Gottschalk
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Alfonso Quintas-Cardama
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Steven Bellon
Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Stuart Duty | ◇ | — | ◇ | — | — | — | ◇ |
Neil J. Gallagher, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Douglas G. Cole, M.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
B. Lynne Parshall | ◇ | — | ◇ | — | — | — | ◇ |
Balkrishan (Simba) Gill, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Michael Mendelsohn, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Thomas J. Lynch Jr., M.D | ◇ | — | ◇ | — | — | — | ◇ |
Scott Biller, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Ian F. Smith | ◇ | — | ◇ | — | — | — | ◇ |
Adrian Gottschalk served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 24, 2026 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Foghorn Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
116 figures on this page: 115 cited to the filing that reported them, 1 calculated from figures it prints.
115 cited to the filing
1 calculated from the filing
Documents cited
- 0001628280-26-045154Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-193928Compensation Discussion and Analysis · Director Compensation · Employment Agreement · Grants of Plan-Based Awards · and 2 more sections
- 0001193125-25-112091Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Foghorn Therapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/FHTX (accessed 2026).
Short form: data: Velarion
The Foghorn Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Foghorn Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}